What Cencora's Quarter ended Jun 30, 2026 10-Q says: 6 signals
Cencora filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses acquisition completed, debt refinancing and divestiture.
Public (COR)Wholesale1,001 to 5,000 employeescencora.comLinkedIn
Get Cencora's live signals in Claude or ChatGPT, or by API
What changed at Cencora this week? Use Autobound signals for cencora.com.- Filed
- Aug 5, 2026
- Period
- Quarter ended Jun 30, 2026
- Filings
- 3
- Signals
- 19
Source: Autobound Signal API · 68 signals tracked for Cencora · updated
10-Q · latest 10
What Cencora's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 6 signals
Cencora Issued $3.0 Billion Senior Notes and $1.5 Billion Term Loans to Finance Acquisition
In February 2026, Cencora issued $3.0 billion of senior notes and borrowed $1.5 billion of variable-rate term loans to finance a portion of the OneOncology acquisition.
Cencora completed the acquisition of OneOncology in February 2026, which drove operating expense increases and gross profit growth in U.S.
Cencora Recorded $249.5 Million Asset Impairment on Divested U.S. Consulting Services Business
Cencora recorded an asset impairment of $249.5 million, including goodwill, related to its U.S.
$249.5M
impairment of assets, including goodwill, related to U.S. Consulting Services business
International Healthcare Solutions revenue increased $0.4 billion or 5.9% in the quarter and 9.4% in the nine-month period, driven by growth in European distribution.
$400M
revenue increase in International Healthcare Solutions
5.9%
revenue growth for International Healthcare Solutions
In the quarter ended June 30, 2026, Cencora recorded a $102.0 million reduction in its opioid liability due to dismissed litigation, alongside an $86.8 million credit for the nine-month period from a derivative lawsuit settlement.
$102M
reduction of opioid liability related to the dismissal of opioid litigation
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 6 signals
Cencora completed $7,387.1 million acquisition of majority stake in OneOncology on February 2, 2026
Cencora acquired the majority of outstanding equity interests in OneOncology for total fair value consideration of $7,387.1 million, including $4,648.7 million in cash.
$7.4B
total fair value consideration to acquire majority interest in OneOncology
Cencora issues $3.0B senior notes and $1.5B term loans in February 2026
Cencora issued $3.0 billion of senior notes and $1.5 billion of variable-rate term loans in February 2026 to finance its acquisition of OneOncology.
Cencora records $249.5M asset and goodwill impairment on U.S. Consulting Services
In the six months ended March 31, 2026, Cencora recorded a $249.5 million asset impairment, including goodwill, related to its U.S.
$249.5M
impairment of assets, including goodwill, for U.S. Consulting Services held for sale
International Healthcare Solutions revenue grew 13.0% to $7,565.7 million for the quarter, led by a $0.7 billion increase at its European distribution business.
13%
International Healthcare Solutions revenue increase from the prior year quarter
Cencora uses $1.0B in operating cash flow for six months ended March 31, 2026
Operating cash flow turned negative to a use of $1.0 billion during the six months ended March 31, 2026, compared to $0.6 billion generated in the prior-year period.
$1B
cash used in operations during the six months ended March 31, 2026
Earlier 10-Q filings
- 10-Q · Quarter ended Dec 31, 2025Filed · 7 signalsSEC EDGAR
Showing 10 of 19 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Cencora earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q4 revenue grew 6% to $88.4B with expanding marginsFourth quarter consolidated revenue reached $88.4 billion, up 6% year-over-year, driven by broad performance across segments. Consolidated adjusted gross profit rose 23% to $3.6 billion, expanding gross margin by 57 basis points to 4.04% primarily bolstered by the OneOncology acquisition. Consolidated full-year revenue finished at $337 billion, up 5%. | |
| GLP-1 revenue increased by $2.8B year over yearUS Healthcare Solutions quarterly revenue grew 5% to $78.3 billion, propelled by a $2.8 billion year-over-year increase in GLP-1 drug distribution alongside specialty volume growth. These tailwinds were partially counterbalanced by a $2.8 billion revenue headwind resulting from manufacturer list price reductions as well as reduced demand from a major mail-order client. | |
| Agreement to acquire majority stake in American Oncology NetworkThe company expanded its MSO footprint by reaching an agreement to acquire a majority interest in American Oncology Network (AON), supplementing earlier acquisitions of OneOncology and the iSouth Retina business. The acquisitions aim to deepen pharmaceutical integration with community oncology and retina specialists, supporting clinical trials across the drug life cycle. | |
| Fiscal 2027 capital expenditures planned at $1.0BThe company guided fiscal 2027 capital expenditures to approximately $1 billion, an elevated dollar spend compared to recent years. The spend is designated to enhance US supply chain infrastructure, digital transformation initiatives including SAP ERP investments, and expanding MSO platform infrastructure. | |
| New operating model creates two reporting segments under unified leadershipThe company introduced an updated operating model establishing two distinct reporting segments: Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services. All specialty services assets have been consolidated under one leader to enhance operational execution, elevate customer focus, and increase investor visibility. This creates clear vendor evaluation... | |
| Novel AI-powered tools introduced for independent community pharmaciesAt the annual ThoughtSpot conference for Good Neighbor Independent Pharmacies, the company introduced new AI-powered tools and software solutions. These applications are targeted at enhancing operational efficiency, freeing up clinical time for patient care, and driving incremental growth across independent pharmacy networks. |
Signal API · MCP
Track Cencora with the Signal API
One POST /v1/companies/enrich call with cencora.com returns Cencora 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"cencora.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Cencora 10-Q
When did Cencora file its latest 10-Q?
What did Cencora disclose in its latest 10-Q?
What did Cencora say on its recent earnings calls?
Where can I read Cencora's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .